ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,953.83
-0.19%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.675
0.00%
Brent Oil
83.76
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Achilles Therapeutics PLC (ACHL)

  7. Achilles Therapeutics PLC (ACHL) ニュース

ACHL

Achilles Therapeutics (ACHL)

Achilles Therapeutics PLC
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ACHL
日付受信時刻ニュースソース見出しコード企業名
2024/05/1806 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
2024/05/1806 : 00GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
2024/05/0820 : 44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
2024/05/0820 : 00GlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
2024/04/0419 : 45GlobeNewswire Inc.Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
2024/04/0419 : 30GlobeNewswire Inc.Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningNASDAQ:ACHLAchilles Therapeutics PLC
2024/02/0521 : 00GlobeNewswire Inc.Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceNASDAQ:ACHLAchilles Therapeutics PLC
2024/02/0203 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
2023/12/1821 : 00GlobeNewswire Inc.Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity PredictionNASDAQ:ACHLAchilles Therapeutics PLC
2023/11/1406 : 36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
2023/11/1406 : 30GlobeNewswire Inc.Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
2023/11/0206 : 26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
2023/09/2305 : 42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
2023/09/2305 : 30GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
2023/09/2021 : 45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ACHLAchilles Therapeutics PLC
2023/08/1804 : 16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
2023/08/0420 : 42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
2023/08/0420 : 00GlobeNewswire Inc.Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
2023/06/3005 : 04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
2023/06/3005 : 03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
2023/06/1221 : 00GlobeNewswire Inc.Achilles Therapeutics to Present at Upcoming ConferencesNASDAQ:ACHLAchilles Therapeutics PLC
2023/05/1021 : 47Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
2023/05/1020 : 15GlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
2023/05/1020 : 00GlobeNewswire Inc.Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell AntigensNASDAQ:ACHLAchilles Therapeutics PLC
2023/04/2607 : 00GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
2023/04/2520 : 00GlobeNewswire Inc.Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA StatusNASDAQ:ACHLAchilles Therapeutics PLC
2023/04/1721 : 00GlobeNewswire Inc.Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:ACHLAchilles Therapeutics PLC
2023/02/1506 : 03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
2023/02/1506 : 02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
2023/02/1320 : 05Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ACHL

最近閲覧した銘柄

EU
5568T
5568T
AMEX
XLL
USOTC
PMMEF
Premium Expl (CE)
BIT
UB6DCE
Unicredit Bank
LSE
IPT
Isis Property Trust
BIT
UI315C
Unicredit Bank
BIT
F14316
Vontobel Financial Produ...
BIT
P1KE46
BNP Paribas Issuance
BIT
TEF
Telefonica
BIT
I05239
BNP Paribas Arbitrage Is...
COIN
BECETH
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有